Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.

Regeneron Pharmaceuticals Inc.
Start price
€762.50
21.08.23 / 50%
Target price
€910.85
21.08.24
Performance (%)
39.08%
End price
€1,060.5
22.08.24
Summary
This prediction ended on 22.08.24 with a price of €1,060.5. The BUY prediction by Canaccord_Genuity_Gr for Regeneron Pharmaceuticals Inc. saw massive gains of 39.08%. Canaccord_Genuity_Gr has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Canaccord_Genuity_Gr has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. -8.451% -8.451% 3.987%
iShares Core DAX® 3.805% 2.249% 2.618%
iShares Nasdaq 100 1.292% 10.522% 36.058%
iShares Nikkei 225® 2.013% 7.253% 50.098%
iShares S&P 500 0.987% 5.713% 25.492%

Comments by Canaccord_Genuity_Gr for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) 39.08%
Target price 910.854
Change
Ends at 21.08.24

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "buy" rating. They now have a $992.00 price target on the stock, up previously from $720.00.
Ratings data for REGN provided by MarketBeat

Canaccord Genuity Group Inc. 
0
Report Share
21.08.23
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) 39.08%
Target price 910.854
Change
Ends at 21.08.24

Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten

Canaccord Genuity Group Inc. 
0
Report Share
22.08.24

Current prediction by Canaccord_Genuity_Gr for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€539.80
19.05.26
€751.63
19.05.27
2.12%
22.05.26

Canaccord Genuity Group Inc. 
19.05.26 50%